Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Johnson & JohnsonRocheAbbott LaboratoriesNovartisEli Lilly and
SymbolNYSE:JNJOTCMKTS:RHHBYNYSE:ABTNYSE:NVSNYSE:LLY
Price Information
Current Price$162.24$42.11$124.35$88.02$189.25
52 Week RangeBuyHoldBuyHoldBuy
MarketRank™
Overall Score2.71.42.42.02.1
Analysis Score3.40.02.43.22.4
Community Score2.52.42.82.32.8
Dividend Score4.22.53.32.52.5
Ownership Score1.70.01.70.01.7
Earnings & Valuation Score1.91.91.91.91.3
Analyst Ratings
Consensus RecommendationBuyHoldBuyHoldBuy
Consensus Price Target$182.62N/A$123.22$108.50$196.40
% Upside from Price Target12.56% upsideN/A-0.91% downside23.27% upside3.78% upside
Trade Information
Market Cap$427.13 billion$288.39 billion$220.29 billion$201.45 billion$181.49 billion
Beta0.70.350.830.590.37
Average Volume8,221,1311,939,9655,157,6861,980,3974,223,955
Sales & Book Value
Annual Revenue$82.06 billion$61.87 billion$31.90 billion$47.50 billion$22.32 billion
Price / Sales5.214.666.904.248.13
Cashflow$11.83 per share$3.06 per share$5.57 per share$7.45 per share$7.23 per share
Price / Cash13.7113.7722.3111.8226.19
Book Value$22.60 per share$5.27 per share$17.70 per share$24.53 per share$2.81 per share
Price / Book7.187.997.033.5967.35
Profitability
Net Income$15.12 billion$13.58 billion$3.69 billion$11.73 billion$8.32 billion
EPS$8.68$2.54$3.24$5.24$6.04
Trailing P/E Ratio25.5116.5865.7928.4930.92
Forward P/E Ratio18.2514.8828.3913.5023.72
P/E Growth3.063.692.061.761.57
Net Margins21.01%N/A10.50%14.71%24.01%
Return on Equity (ROE)34.64%N/A18.19%24.39%166.45%
Return on Assets (ROA)13.40%N/A8.29%10.59%15.18%
Dividend
Annual Payout$4.04$0.77$1.80$2.08$3.40
Dividend Yield2.49%1.83%1.45%2.36%1.80%
Three-Year Dividend Growth19.88%N/A35.85%13.60%42.31%
Payout Ratio46.54%30.31%55.56%39.69%56.29%
Years of Consecutive Dividend Growth59 YearsN/A49 Years1 Years1 Years
Debt
Debt-to-Equity Ratio0.51%0.36%0.58%0.49%3.27%
Current Ratio1.48%1.23%1.70%0.91%1.36%
Quick Ratio1.24%0.93%1.19%0.69%1.06%
Ownership Information
Institutional Ownership Percentage67.25%0.32%72.58%9.86%75.59%
Insider Ownership Percentage0.27%N/A1.70%0.01%0.09%
Miscellaneous
Employees134,500101,465109,000105,79435,000
Shares Outstanding2.63 billion6.85 billion1.77 billion2.29 billion958.99 million
Next Earnings Date4/20/2021 (Confirmed)N/A4/20/2021 (Confirmed)4/27/2021 (Confirmed)4/27/2021 (Confirmed)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Lilly Seeks to Revoke Emergency Use Authorization for COVID-fighting AntibodyLilly Seeks to Revoke Emergency Use Authorization for COVID-fighting Antibody
insideindianabusiness.com - April 16 at 6:33 PM
The Latest: Decreasing demand for vaccines in KansasThe Latest: Decreasing demand for vaccines in Kansas
marketbeat.com - April 16 at 5:08 PM
The Latest: Infections in Turkey soar to record levelsThe Latest: Infections in Turkey soar to record levels
marketbeat.com - April 16 at 1:55 PM
Eli Lilly: Antibody combo works best on COVID-19 variantsEli Lilly: Antibody combo works best on COVID-19 variants
ibj.com - April 16 at 1:33 PM
Eli Lillys Olympic athletes share health challenge stories in the countdown to GamesEli Lilly's Olympic athletes share health challenge stories in the countdown to Games
fiercepharma.com - April 16 at 1:33 PM
Eli Lilly asks FDA to revoke approval for use of antibody drug by itselfEli Lilly asks FDA to revoke approval for use of antibody drug by itself
upi.com - April 16 at 1:33 PM
The Latest: WH: $4B to American Indian tribes for virusThe Latest: WH: $4B to American Indian tribes for virus
marketbeat.com - April 16 at 1:08 PM
The Latest: US sets up $1.7B network to track virus variantsThe Latest: US sets up $1.7B network to track virus variants
marketbeat.com - April 16 at 12:38 PM
The Latest: Eli Lilly: Antibody combo works best on variantsThe Latest: Eli Lilly: Antibody combo works best on variants
marketbeat.com - April 16 at 10:36 AM
Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimabLilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab
news.trust.org - April 16 at 8:33 AM
Lilly asks FDA to revoke authorization for lone use of COVID-19 drug bamlanivimabLilly asks FDA to revoke authorization for lone use of COVID-19 drug bamlanivimab
reuters.com - April 16 at 8:33 AM
New Covid-19 Strains Prompt Lilly to Seek to End U.S. Use of Single Antibody Drug AloneNew Covid-19 Strains Prompt Lilly to Seek to End U.S. Use of Single Antibody Drug Alone
wsj.com - April 16 at 8:33 AM
BRIEF-Lilly Requests Revocation Of Emergency Use Authorization For Bamlanivimab Alone To Complete Transition To Bamlanivimab And Etesevimab Together For Treatment Of Covid-19 ...BRIEF-Lilly Requests Revocation Of Emergency Use Authorization For Bamlanivimab Alone To Complete Transition To Bamlanivimab And Etesevimab Together For Treatment Of Covid-19 ...
msn.com - April 16 at 8:33 AM
Eli Lil­ly asks FDA to re­voke EUA for Covid-19 treat­mentEli Lil­ly asks FDA to re­voke EUA for Covid-19 treat­ment
endpts.com - April 16 at 8:33 AM
Eli Lilly Requests FDA Revoke EUA For Bamlanivimab 700 Mg Alone - Quick FactsEli Lilly Requests FDA Revoke EUA For Bamlanivimab 700 Mg Alone - Quick Facts
nasdaq.com - April 16 at 8:33 AM
Lilly asks FDA to revoke authorization for COVID-19 antibody bamlanivimab aloneLilly asks FDA to revoke authorization for COVID-19 antibody bamlanivimab alone
news.yahoo.com - April 16 at 8:33 AM
Eli Lilly asks FDA to revoke EUA for COVID antibody treatment alone to speed transition to combination therapyEli Lilly asks FDA to revoke EUA for COVID antibody treatment alone to speed transition to combination therapy
msn.com - April 16 at 8:33 AM
Eli Lilly asks FDA to revoke authorization for lone use of Covid-19 drugEli Lilly asks FDA to revoke authorization for lone use of Covid-19 drug
cnbc.com - April 16 at 8:33 AM
SciNeuro and Eli Lilly sign exclusive license agreement for alpha-synuclein in Greater ChinaSciNeuro and Eli Lilly sign exclusive license agreement for alpha-synuclein in Greater China
pharmaceutical-business-review.com - April 15 at 7:18 PM
Chemical Pharmaceutical Market May See Big Move | GlaxoSmithKline, AstraZeneca, Eli LillyChemical Pharmaceutical Market May See Big Move | GlaxoSmithKline, AstraZeneca, Eli Lilly
openpr.com - April 15 at 9:17 AM
A year after buyout, Lilly to shutter Dermiras Menlo Park facility and shed 163 jobsA year after buyout, Lilly to shutter Dermira's Menlo Park facility and shed 163 jobs
fiercepharma.com - April 14 at 2:52 PM
Small Molecule Cancer Drug Market Size Analysis by Competitive landscape and Insights for next 5 yearsSmall Molecule Cancer Drug Market Size Analysis by Competitive landscape and Insights for next 5 years
marketwatch.com - April 14 at 9:52 AM
SciNeuro Pharmaceuticals Announces Exclusive Licensing Agreement with Eli Lilly & CompanySciNeuro Pharmaceuticals Announces Exclusive Licensing Agreement with Eli Lilly & Company
apnews.com - April 14 at 9:52 AM
FY2024 Earnings Estimate for Eli Lilly and Company Issued By Truist Securiti (NYSE:LLY)FY2024 Earnings Estimate for Eli Lilly and Company Issued By Truist Securiti (NYSE:LLY)
americanbankingnews.com - April 14 at 9:34 AM
A host of mutations could compromise COVID-19 vaccines and antibody therapiesA host of mutations could compromise COVID-19 vaccines and antibody therapies
news-medical.net - April 13 at 11:50 PM
AveXis name recognition and Zolgensma legacy hook Lilly in Jaguars $139M series BAveXis name recognition and Zolgensma legacy hook Lilly in Jaguar's $139M series B
fiercebiotech.com - April 13 at 1:47 PM
Diogo Rau to Join Lilly as Senior VP, CIODiogo Rau to Join Lilly as Senior VP, CIO
insideindianabusiness.com - April 13 at 1:47 PM
Eli Lilly, riding pharmas rising digital wave, drafts Apple exec to replace Shah as CEOEli Lilly, riding pharma's rising digital wave, drafts Apple exec to replace Shah as CEO
fiercepharma.com - April 13 at 1:47 PM
Eli Lilly and Company hires Apples retail information technology chiefEli Lilly and Company hires Apple's retail information technology chief
appleinsider.com - April 13 at 1:47 PM
Longeveron: A High-Quality Emerging Biotech PlayLongeveron: A High-Quality Emerging Biotech Play
finance.yahoo.com - April 13 at 1:47 PM
3 Recession-Proof Dividend Stocks to Buy Now (LLY)3 Recession-Proof Dividend Stocks to Buy Now (LLY)
marketbeat.com - February 1 at 5:14 PM
Follow Eli Lillys (NYSE:LLY) Lead, and Make a  Big PurchaseFollow Eli Lilly's (NYSE:LLY) Lead, and Make a Big Purchase
marketbeat.com - December 15 at 11:42 AM
How to Invest After a Turbulent 2020 Election (LLY)How to Invest After a Turbulent 2020 Election (LLY)
marketbeat.com - November 23 at 5:51 PM
Amgen (NASDAQ:AMGN) Proves the Value of Diversification (LLY)Amgen (NASDAQ:AMGN) Proves the Value of Diversification (LLY)
marketbeat.com - October 29 at 11:54 AM
DateCompanyBrokerageAction
1/27/2021Johnson & JohnsonJPMorgan Chase & Co.Boost Price Target
1/27/2021Johnson & JohnsonCredit Suisse GroupBoost Price Target
1/27/2021Johnson & JohnsonRaymond JamesBoost Price Target
1/27/2021Johnson & JohnsonCowenBoost Price Target
1/27/2021Johnson & JohnsonMorgan StanleyBoost Price Target
1/27/2021Johnson & JohnsonSVB LeerinkBoost Price Target
1/27/2021Johnson & JohnsonWells Fargo & CompanyBoost Price Target
1/26/2021Johnson & JohnsonCantor FitzgeraldBoost Price Target
8/19/2020Johnson & JohnsonStifel NicolausDowngrade
7/20/2020Johnson & JohnsonBank of AmericaReiterated Rating
7/20/2020Johnson & JohnsonIndependent ResearchUpgrade
7/17/2020Johnson & JohnsonCitigroupBoost Price Target
4/29/2020Johnson & JohnsonBarclaysBoost Price Target
3/16/2021RocheJefferies Financial GroupDowngrade
3/5/2021RocheErste GroupDowngrade
2/25/2021RocheBerenberg BankReiterated Rating
2/17/2021RocheUBS GroupDowngrade
2/4/2021RocheOddo BhfDowngrade
1/15/2021RocheDeutsche Bank AktiengesellschaftInitiated Coverage
9/28/2020RocheSociete GeneraleReiterated Rating
7/13/2020RocheSanford C. BernsteinInitiated Coverage
7/3/2020RocheAlphaValueUpgrade
5/13/2020RocheWolfe ResearchUpgrade
4/30/2020RocheHSBCUpgrade
4/15/2021Abbott LaboratoriesAtlantic SecuritiesInitiated Coverage
1/28/2021Abbott LaboratoriesBTIG ResearchUpgrade
9/2/2020Abbott LaboratoriesThe Goldman Sachs GroupSet Price Target
3/16/2021NovartisArgusReiterated Rating
3/22/2021Eli Lilly andTruist SecuritiesBoost Price Target
2/1/2021Eli Lilly andMizuhoBoost Price Target
6/16/2020Eli Lilly andGuggenheimUpgrade
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.